Search

Nowadays, it is more important than ever to meet the increasing technical and statutory requirements and to develop new process strategies. In sheet metal forming the low consumption of oil lubrication gets an increasingly important role. The aim in sheet metal forming is to reduce the amounts of lubricants. In the long term, the future sheet metal processing should be able to completely dispense without mineral oil-containing lubricants. Two promising approaches for a dry process design are combined in this paper for the first time and the fundamental feasibility of this new hybrid technology is shown. On the one hand, a novel approach for temporary lubrication of deep-drawing processes with CO2 as a volatile medium is used. On the other hand, it is supported by the application of an additional hard coating system such as a silicon nitride (Si3N4) or tungsten doped a-C:H multilayered (Cr/CrNx/a-C:H:W/a-C:H) coating system to further reduce tool wear and wear debris of the formed sheets made of DC04 (mat. no.: 1.0338). The results show a low coefficient of friction and reduced wear. Especially for the carbon coating system, there is minor tool wear at a higher surface pressure. By means of the graphite constituent, even a smoothening of the roughness peaks can be recorded. The next step would be the implementation of this hybrid technology on a tool for deep drawing a rectangular cup.

Novel, highly potent CXCR4 inhibitors with good pharmacokinetic properties were obtained by applying PEM technology starting from the naturally occurring ?-hairpin peptide polyphemusin II. The design involved incorporation of key residues from polyphemusin II into a macrocyclic template-bound ?-hairpin mimetic. Using a parallel synthesis approach, the potency and ADME properties of the mimetics were optimized, resulting in CXCR4 inhibitors such as POL2438 and POL3026. Their activities were confirmed in a series of in vitro HIV-1 infection assays. Besides high selectivity for CXCR4, POL3026 had excellent plasma stability and favorable pharmacokinetic properties in dogs. In a murine model POL3026 was highly efficacious in hematopoietic stem cell mobilization. Hence, PEM-based CXCR4 inhibitors have the potential to become therapeutic agents for the treatment of HIV infections (as entry inhibitor), cancer (e.g. for inhibition of metastasis), stem cell transplant and inflammation.